You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Improving CV Outcomes in Patients With Coronary and Vascular Disease Using Antithrombotic Strategies: How Well Are We Doing?

  • Authors: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI; Craig I. Coleman, PharmD, FASHP, FACC; Marc P. Bonaca, MD, MPH
  • CME / ABIM MOC / CE Released: 7/27/2023
  • Valid for credit through: 7/27/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    Nurses - 0.50 ANCC Contact Hour(s) (0.25 contact hours are in the area of pharmacology)

    Pharmacists - 0.50 Knowledge-based ACPE (0.050 CEUs)

    IPCE - 0.50 Interprofessional Continuing Education (IPCE) credit

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for cardiologists, surgeons, primary care physicians, hematologists and oncologists, nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care of patients with atrial fibrillation, venous thromboembolism, coronary artery disease (CAD), or peripheral artery disease (PAD).

The goal of this activity is for learners to be better able to evaluate the latest evidence and guidelines for the use of novel antithrombotic strategies for the treatment of patients with CAD and/or PAD, understand strategies to overcome clinical inertia, and integrate the latest evidence and guidelines into individualized treatment plans for patients with CAD/PAD to reduce the risk of adverse CV and/or limb events.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Novel treatment strategies in patients with CAD/PAD
    • Guideline recommendations for the use of antithrombotic therapy to treat CAD/PAD
  • Have greater competence related to
    • Selecting antithrombotic therapy for patients with CAD/PAD that has demonstrated benefit in improving outcomes in accordance with the latest clinical practice guidelines and evidence
  • Demonstrate greater confidence in their ability to
    • Work with the interprofessional team to integrate appropriate use of antithrombotic therapy in the treatment of patients with CAD/PAD


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.


Moderator

  • Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI

    Director of Mount Sinai Heart
    Dr. Valentin Fuster Professor of Cardiovascular Medicine
    Icahn School of Medicine at Mount Sinai Health System
    New York, New York

    Disclosures

    Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI, has the following relevant financial relationships: 
    Consultant or advisor for: Angiowave; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Broadview Ventures; Cardax; CellProthera; Cereno Scientific; High Enroll; Hims, Inc.; Janssen; Level Ex; McKinsey & Company; Merck; MyoKardia; NirvaMed; Novo Nordisk; PhaseBio Pharmaceuticals, Inc.; PLx Pharma, Inc.; Regado Biosciences; Stasys
    Research funding from: Abbott; Acesion Pharma; Afimmune Limited; Aker Biomarine; Amarin Corporation plc; Amgen Inc.; AstraZeneca; Bayer; Beren; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; Cardax; CellProthera; Cereno Scientific; Chiesi; CinCor; Cleerly; CSL Behring; Eisai Inc.; Ethicon; Faraday Pharmaceuticals; Ferring Pharmaceuticals; Forest Laboratories, Inc.; Fractyl Laboratories, Inc.; Garmin; HLS Therapeutics; Idorsia Pharmaceuticals, Ltd.; Ironwood Pharmaceuticals, Inc.; Ischemix, Inc.; Janssen; Javelin; Lexicon Pharmaceuticals, Inc.; Lilly; Medtronic, Inc.; Merck; Moderna, Inc.; MyoKardia; NirvaMed; Novartis Pharmaceuticals; Novo Nordisk; Owkin; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PLx Pharma, Inc.; Recardio; Regeneron Pharmaceuticals, Inc.; Roche; Sanofi; Stasys; Synaptic; The Medicines Company; Youngene; 89Bio
    Contracted researcher for: Abbott; BIOTRONIK; Boston Scientific; CSI; Endotronix; St. Jude Medical (now Abbott); Philips; SpectraWAVE; Svelte; Vascular Solutions
    Patent beneficiary of: Sotagliflozin
    Stock options from: Angiowave; DRS.LINQ
    Owns stock (privately owned) in: High Enroll
    Owns stock (publicly traded) in: Bristol Myers Squibb Company
    Other: Board of Directors: Angiowave; Bristol Myers Squibb Company; DRS.LINQ; High Enroll; TobeSoft; Data Safety Monitoring Committees: Acesion Pharma; Boston Scientific; Contego Medical; Novartis

Faculty

  • Craig I. Coleman, PharmD, FASHP, FACC

    Professor, University of Connecticut
    Director, Evidence-Based Practice Center
    Hartford Hospital 
    Hartford, Connecticut

    Disclosures

    Craig I. Coleman, PharmD, FASHP, FACC, has the following relevant financial relationships: 
    Consultant or advisor for: Bayer AG
    Research funding from: AstraZeneca; Bayer AG; Janssen Scientific Affairs LLC 
    Contracted researcher for: AstraZeneca; Bayer AG; Janssen Scientific Affairs LLC

  • Marc P. Bonaca, MD, MPH

    Professor of Medicine, Cardiology and Vascular Medicine
    Director, Vascular Research
    University of Colorado School of Medicine
    Executive Director, CPC Clinical Research
    Aurora, Colorado

    Disclosures

    Marc P. Bonaca, MD, MPH, has the following relevant financial relationships: 
    Consultant or advisor for: Audentes Therapeutics, Inc.
    Research funding from: Abbott Laboratories; Adamis Pharmaceuticals Corporation; Agios Pharmaceuticals; Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc; Amgen Inc.; Angionetics, Inc.; ARCA Biopharma, Inc.; Array BioPharma; AstraZeneca; Audentes Thereapeutics, Inc.; Bayer; Better Therapeutics; Boston Clinical Research Institute; Bristol Myers Squibb Company; Cambrian Biopharma, Inc.; Cardiol Therapeutics Inc.; CellResearch Corp.; Cook Medical Inc; Covance; CSL Behring; Eidos Therapeutics, Inc.; EP Trading Co. Ltd.; EPG Communication Holdings Ltd.; Epizon Pharma, Inc.; Esperion Therapeutics, Inc.; Everly Well, Inc.; Exicon Consulting Pvt. Ltd.; Faraday Pharmaceuticals, Inc.; Foresee Pharmaceuticals Co. Ltd.; Fortress Biotech, Inc.; HDL Therapeutics; Hummingbird Bioscience; Insmed Incorporated; Ionis Pharmaceuticals; IQVIA Inc.; JanOne Biotech Holdings Inc.; Janssen Biotech, Inc.; Kaneka; Kowa Company Ltd.; Lexicon Pharmaceuticals, Inc.; MedImmune Inc.; Medpace, Inc.; Merck; Novartis Pharmaceuticals; Novate Medical, Ltd; Novo Nordisk; Pan Industry Group; Pfizer, Inc.; PhaseBio Pharmaceuticals, Inc.; PPD Development, LP Pharma; Prothena Biosciences Limited; Regeneron Pharmaceuticals, Inc.; Regio Biosciences, Inc.; Rexgenero; Sanifit Therapeutics S.A.; Sanofi; Silence Therapeutics PLC; Smith & Nephew; Stealth BioTherapeutics Inc.; VarmX; Worldwide Clinical Trials Inc.; WraSer, LLC
    Owns stock (publicly traded) in: Medtronic, Inc.; Pfizer, Inc. 

Editors

  • Joy P. Marko, MS, APN-C, CCMEP

    Senior Medical Education Director, Medscape, LLC 

    Disclosures

    Joy P. Marko, MS, APN-C, CCMEP, has no relevant financial relationships.

  • Frederick Stange, DO

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Frederick Stange, DO, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 0.50 Interprofessional Continuing Education (IPCE) credit for learning and change.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

    For Pharmacists

  • Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: JA0007105-0000-23-252-H01-P).

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Improving CV Outcomes in Patients With Coronary and Vascular Disease Using Antithrombotic Strategies: How Well Are We Doing?

Authors: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI; Craig I. Coleman, PharmD, FASHP, FACC; Marc P. Bonaca, MD, MPHFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/27/2023

Valid for credit through: 7/27/2024, 11:59 PM EST

processing....

Educational Impact Challenge

Please answer the questions below to self-assess your knowledge. Answering these questions again after the activity will allow you to see what you learned.

  • Print